Apatinib Mesylate and Camrelizumab Combined With TACE as Neoadjuvant Therapy for Hepatocellular Carcinoma

Name: Apatinib Mesylate and Camrelizumab Combined With TACE as Neoadjuvant Therapy for Hepatocellular Carcinoma
License: Public Domain

Wei Zhang

ClinicalTrials.gov · Datasets · License: Public Domain

hepatocellular carcinoma (hcc)

This document is indexed with metadata only — full text is not available in the archive for this record. Open the official source ↗

Record · ID 230405
Retrieved via Conceptio — every document is proof-bundled with source, license, and retrieval metadata.